NeoGenomics (NEO) to Release Quarterly Earnings on Tuesday

NeoGenomics (NASDAQ:NEO) is expected to announce its Q4 2025 results before the market opens on Tuesday, February 17th. Analysts expect the company to announce earnings of $0.04 per share and revenue of $188.2460 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, February 17, 2026 at 8:30 AM ET.

NeoGenomics Stock Performance

NASDAQ:NEO opened at $11.38 on Monday. The firm has a market capitalization of $1.47 billion, a PE ratio of -12.93 and a beta of 1.58. NeoGenomics has a 1 year low of $4.72 and a 1 year high of $14.73. The company has a current ratio of 3.91, a quick ratio of 3.62 and a debt-to-equity ratio of 0.41. The firm’s fifty day simple moving average is $12.18 and its 200 day simple moving average is $10.02.

Insider Activity at NeoGenomics

In related news, COO Warren Stone sold 22,128 shares of the company’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $12.50, for a total value of $276,600.00. Following the completion of the transaction, the chief operating officer directly owned 121,631 shares in the company, valued at approximately $1,520,387.50. This represents a 15.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Alicia C. Olivo sold 20,916 shares of NeoGenomics stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $12.00, for a total transaction of $250,992.00. Following the sale, the executive vice president owned 31,083 shares in the company, valued at $372,996. This represents a 40.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 2.40% of the stock is currently owned by company insiders.

Institutional Trading of NeoGenomics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Headlands Technologies LLC bought a new position in NeoGenomics during the second quarter worth about $32,000. Caitong International Asset Management Co. Ltd raised its holdings in shares of NeoGenomics by 110.2% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,968 shares of the medical research company’s stock worth $35,000 after buying an additional 1,556 shares in the last quarter. Kestra Advisory Services LLC acquired a new position in shares of NeoGenomics in the 4th quarter worth approximately $39,000. Smartleaf Asset Management LLC lifted its position in shares of NeoGenomics by 77.7% during the 4th quarter. Smartleaf Asset Management LLC now owns 3,466 shares of the medical research company’s stock worth $42,000 after buying an additional 1,515 shares during the period. Finally, Van ECK Associates Corp boosted its stake in NeoGenomics by 113.8% in the 4th quarter. Van ECK Associates Corp now owns 4,921 shares of the medical research company’s stock valued at $58,000 after buying an additional 2,619 shares in the last quarter. Institutional investors own 98.50% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on NEO. Leerink Partners set a $14.00 price objective on NeoGenomics in a research note on Tuesday, October 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NeoGenomics in a report on Monday, December 29th. Zacks Research upgraded NeoGenomics from a “hold” rating to a “strong-buy” rating in a report on Monday, January 12th. TD Cowen reissued a “buy” rating on shares of NeoGenomics in a research report on Wednesday, January 7th. Finally, Needham & Company LLC restated a “buy” rating and issued a $14.00 price objective on shares of NeoGenomics in a research note on Monday, January 12th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, NeoGenomics has a consensus rating of “Hold” and a consensus target price of $12.00.

NeoGenomics Company Profile

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.